AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19496103 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day plus celecoxib 400 mg/day (200 mg bid)
Number of subjects: 40
Study 19496103 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 40 mg/day plus placebo
Number of subjects: 40
Study 17992915 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Pokemon (Colgate‐Palmolive, Thailand)
Number of subjects: 21
Study 17992915 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioe Children's Toothpaste (LG, Korea)
Number of subjects: 21
Study 17992915 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicco (Vicco Laboratories, India)
Number of subjects: 21
Study 17992915 — intervention group
Group type: COMPARATOR
Intervention: Control Group (not explicitly mentioned)
Number of subjects: 21
Study 15691622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM)
Number of subjects: 150
Study 15691622 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 150
Study 15691622 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 150
Study 15691622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for women
Number of subjects: 150
Study 15691622 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) for men
Number of subjects: 150
Study 11915064 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion (10 mL/h)
Number of subjects: 50
Study 11915064 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (5 mL/h basal rate with 5 mL bolus every 60 minutes)
Number of subjects: 50
Study 9620430 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy
Number of subjects: 15
Study 9620430 — intervention group
Group type: COMPARATOR
Intervention: Follow-up only
Number of subjects: 15
Study 7890496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vistech-Teller Acuity Cards (TAC) for binocular and monocular grating visual acuity (VA)
Number of subjects: 646
Study 7890496 — intervention group
Group type: EXPERIMENTAL
Intervention: Vistech-Teller Acuity Cards (TAC)
Number of subjects: 646
Study 1978475 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride CR (385 mg daily)
Number of subjects: 114
Study 1978475 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol (17 mg daily)
Number of subjects: 114
Study 1978475 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 114
Study 1978475 — intervention group
Group type: EXPERIMENTAL
Intervention: Remoxipride CR
Number of subjects: 114
Study 7398099 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 micrograms 1 alpha(OH)D3
Number of subjects: 20
Study 7398099 — intervention group
Group type: COMPARATOR
Intervention: 0.5 micrograms 1 alpha(OH)D3
Number of subjects: 20
Study 31838259 — intervention group
Group type: EXPERIMENTAL
Intervention: Education and household training on best-burn practices (Tx1)
Number of subjects: 0
Study 31838259 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor air filtration unit (Tx2)
Number of subjects: 0
Study 31838259 — intervention group
Group type: COMPARATOR
Intervention: Control arm (Tx3)
Number of subjects: 0
Study 31800542 — intervention group
Group type: EXPERIMENTAL
Intervention: Crofelemer (125 mg)
Number of subjects: 240
Study 31800542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study 28131677 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-layer amniotic membrane transplantation
Number of subjects: 99
Study 28131677 — intervention group
Group type: COMPARATOR
Intervention: Routine antibacterial therapy
Number of subjects: 99
Study 25890359 — intervention group
Group type: EXPERIMENTAL
Intervention: Particle-filtered air exposure
Number of subjects: 60
Study 25890359 — intervention group
Group type: COMPARATOR
Intervention: Sham-filtered air exposure
Number of subjects: 60
Study 23806933 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin sealant plus self-adhesive fabric dressing
Number of subjects: 50
Study 23806933 — intervention group
Group type: COMPARATOR
Intervention: Self-adhesive fabric dressing only (control)
Number of subjects: 50
Study 17699383 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 547
Study 17699383 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher log IL-6
Number of subjects: 547
Study 17699383 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher APACHE II score
Number of subjects: 547
Study 17699383 — intervention group
Group type: EXPERIMENTAL
Intervention: Dependence on activity of daily living scale
Number of subjects: 547
Study 17699383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline platelet count
Number of subjects: 547
Study 17699383 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline respiratory Sepsis Organ Failure Assessment score
Number of subjects: 547
Study 17699383 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 547
Study 15219887 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days
Number of subjects: 134
Study 15219887 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (CC) 100 mg daily for 5 days + phytoestrogens (PE) 1500 mg daily for 10 days
Number of subjects: 134
Study 10798461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined behavioral and drug therapy (biofeedback-assisted behavioral training followed by oxybutynin chloride titrated from 2.5 mg to 15 mg daily)
Number of subjects: 197
Study 10798461 — intervention group
Group type: COMPARATOR
Intervention: Drug therapy (oxybutynin chloride)
Number of subjects: 197
Study 10798461 — intervention group
Group type: COMPARATOR
Intervention: Behavioral treatment
Number of subjects: 197
Study 10798461 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined drug and behavioral treatment
Number of subjects: 197
Study 8831328 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 250 micrograms/kg
Number of subjects: 70
Study 8831328 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium 600 micrograms/kg
Number of subjects: 70
Study 8831328 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 100 micrograms/kg
Number of subjects: 70
Study 8831328 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium 250 micrograms/kg after rocuronium
Number of subjects: 70
Study 8831328 — intervention group
Group type: COMPARATOR
Intervention: Mivacurium 250 micrograms/kg after vecuronium
Number of subjects: 70
Study 8831328 — intervention group
Group type: COMPARATOR
Intervention: Vecuronium after mivacurium
Number of subjects: 70
Study 8831328 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium after mivacurium
Number of subjects: 70
Study 1305819 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of 6 puffs (1500 micrograms) of terbutaline
Number of subjects: 30
Study 1305819 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 2 puffs (500 micrograms) of terbutaline at 15-minute intervals
Number of subjects: 30
Study 1305819 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 doses of 2 puffs (500 micrograms) of terbutaline at 5-minute intervals
Number of subjects: 30
Study 1305819 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study 3888153 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticlopidine
Number of subjects: 15
Study 3888153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 31939036 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal botulinum toxin A (50 units)
Number of subjects: 20
Study 31939036 — intervention group
Group type: COMPARATOR
Intervention: Fractional microneedle radiofrequency (FMR)
Number of subjects: 20
Study 31391076 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific rehabilitation programme combining relearning of motor control and self-management strategies
Number of subjects: 50
Study 31391076 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 50
Study 31391076 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific rehabilitation programme
Number of subjects: 50
Study 27995626 — intervention group
Group type: EXPERIMENTAL
Intervention: PVC tracheal tube
Number of subjects: 177
Study 27995626 — intervention group
Group type: EXPERIMENTAL
Intervention: Reinforced tracheal tube
Number of subjects: 177
Study 27995626 — intervention group
Group type: EXPERIMENTAL
Intervention: BlockBuster tracheal tube
Number of subjects: 177
Study 25578925 — intervention group
Group type: EXPERIMENTAL
Intervention: CM+CHW
Number of subjects: 207
Study 25578925 — intervention group
Group type: EXPERIMENTAL
Intervention: CM
Number of subjects: 207
Study 25578925 — intervention group
Group type: COMPARATOR
Intervention: UC
Number of subjects: 207
Study 25578925 — intervention group
Group type: EXPERIMENTAL
Intervention: CM+CHW (men)
Number of subjects: 207
Study 23701209 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 19
Study 23701209 — intervention group
Group type: COMPARATOR
Intervention: Control session
Number of subjects: 19
Study 21820521 — intervention group
Group type: EXPERIMENTAL
Intervention: IA-BioHA
Number of subjects: 433
Study 21820521 — intervention group
Group type: COMPARATOR
Intervention: IA-SA
Number of subjects: 433
Study 19138360 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfuzosin 10 mg once a day
Number of subjects: 66
Study 19138360 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg on alternative days
Number of subjects: 66
Study 19138360 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of alfuzosin and tadalafil
Number of subjects: 66
Study 16960448 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (40 mg/day)
Number of subjects: 23
Study 16960448 — intervention group
Group type: COMPARATOR
Intervention: Pravastatin (80 mg/day)
Number of subjects: 23
Study 15063917 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 67
Study 15063917 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 11190581 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril 20 mg/day (n = 12)
Number of subjects: 24
Study 11190581 — intervention group
Group type: COMPARATOR
Intervention: Non-quinapril group (n = 12)
Number of subjects: 24
Study 11190581 — intervention group
Group type: EXPERIMENTAL
Intervention: Quinapril group
Number of subjects: 24
Study 11190581 — intervention group
Group type: COMPARATOR
Intervention: Non-quinapril group
Number of subjects: 24
Study 9332997 — intervention group
Group type: EXPERIMENTAL
Intervention: Dopamine infusion at a rate of 1 to 5 microg/kg per minute
Number of subjects: 40
Study 9332997 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile water)
Number of subjects: 40
Study 8404293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin/sulbactam
Number of subjects: 422
Study 8404293 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 422
Study 8404293 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin/metronidazole
Number of subjects: 422
Study 8404293 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 422
Study 2877643 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockade with betaxolol (oral, cardioselective) during clinical beta-blockade (heart rate 50 to 60 beats per minute, <20% increase in heart rate over baseline during stage I treadmill exercise, Bruce protocol)
Number of subjects: 22
Study 2877643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 31807900 — intervention group
Group type: EXPERIMENTAL
Intervention: NMES at short muscle length (50°)
Number of subjects: 10
Study 31807900 — intervention group
Group type: COMPARATOR
Intervention: NMES at long muscle length (100°)
Number of subjects: 10
Study 29763434 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ibuprofen 3 times a day for 3 days
Number of subjects: 383
Study 29763434 — intervention group
Group type: COMPARATOR
Intervention: 200 mg pivmecillinam 3 times a day for 3 days
Number of subjects: 383
Study 27150261 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-981 (0.3, 1, 3, or 10 mg/kg intravenously; 0.3, 1, 3 mg/kg subcutaneously)
Number of subjects: 92
Study 27150261 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-981 (3 mg/kg subcutaneously every 4 weeks)
Number of subjects: 92
Study 27150261 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-981 (subcutaneous doses every 2 weeks)
Number of subjects: 92
Study 27150261 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-981
Number of subjects: 92
Study 27150261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 24844765 — intervention group
Group type: EXPERIMENTAL
Intervention: LEOPIN ROYAL® (LER)
Number of subjects: 49
Study 24844765 — intervention group
Group type: COMPARATOR
Intervention: Kampo (mainly kamishoyosan)
Number of subjects: 49
Study 21638159 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk reduction counselling intervention (one session, 180 min)
Number of subjects: 150
Study 21638159 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 150
Study 19661958 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet + 500 ml water prior to each daily meal (water group)
Number of subjects: 48
Study 19661958 — intervention group
Group type: COMPARATOR
Intervention: Hypocaloric diet alone (nonwater group)
Number of subjects: 48
Study 19661958 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 ml water preload (WP)
Number of subjects: 48
Study 18598003 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg of bimosiamose
Number of subjects: 16
Study 18598003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 15860254 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (low doses) added to standard of care
Number of subjects: 0
Study 15860254 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone (selective MR antagonist)
Number of subjects: 0
Study 12578923 — intervention group
Group type: EXPERIMENTAL
Intervention: Right mesial temporal sclerosis (MTS)
Number of subjects: 146
Study 12578923 — intervention group
Group type: COMPARATOR
Intervention: Left MTS, right or left temporal lobe lesions other than MTS, or extratemporal seizure foci
Number of subjects: 146
Study 12578923 — intervention group
Group type: EXPERIMENTAL
Intervention: All subjects with right TLE
Number of subjects: 146
Study 10593458 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated gas insufflation (37 degrees C)
Number of subjects: 37
Study 10593458 — intervention group
Group type: COMPARATOR
Intervention: Unheated gas insufflation (24 degrees C)
Number of subjects: 37
Study 8694020 — intervention group
Group type: COMPARATOR
Intervention: 0 g lactose (lactose-free milk)
Number of subjects: 39
Study 8694020 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g lactose
Number of subjects: 39
Study 8694020 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g lactose
Number of subjects: 39
Study 8694020 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 g lactose
Number of subjects: 39
Study 8694020 — intervention group
Group type: COMPARATOR
Intervention: lactose-free milk
Number of subjects: 39
Study 1687254 — intervention group
Group type: COMPARATOR
Intervention: Incision and banding
Number of subjects: 30
Study 1687254 — intervention group
Group type: EXPERIMENTAL
Intervention: Emergency haemorrhoidectomy
Number of subjects: 30
Study 6577031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque control instructions using the modified Bass brushing technique with no disclosant
Number of subjects: 24
Study 6577031 — intervention group
Group type: EXPERIMENTAL
Intervention: Plaque control instructions supplemented with instructions in the use of a Plaklite
Number of subjects: 24
Study 6577031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured plaque control instructions)
Number of subjects: 24
Study 29499976 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 μg/week sublingual vitamin B12 (Ld)
Number of subjects: 40
Study 29499976 — intervention group
Group type: COMPARATOR
Intervention: 2000 μg/week sublingual vitamin B12 (Hd)
Number of subjects: 40
Study 28093634 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bisphosphonates therapy
Number of subjects: 0
Study 28093634 — intervention group
Group type: EXPERIMENTAL
Intervention: Measurement of bone turnover markers (BTMs) PINP and CTX at baseline and 3 months after starting therapy
Number of subjects: 0
Study 26094080 — intervention group
Group type: EXPERIMENTAL
Intervention: Panitumumab (9 mg/kg) in combination with pemetrexed (500 mg/m²) and cisplatin (75 mg/m²)
Number of subjects: 96
Study 26094080 — intervention group
Group type: COMPARATOR
Intervention: Pemetrexed and cisplatin (control group)
Number of subjects: 96
Study 24144572 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint stimulation (auricular acupressure combined with transcutaneous electric acupoint stimulation at true acupoint)
Number of subjects: 90
Study 24144572 — intervention group
Group type: COMPARATOR
Intervention: Sham group (acupoint stimulation at sham acupoint without embedding seeds)
Number of subjects: 90
Study 24144572 — intervention group
Group type: COMPARATOR
Intervention: Control group (no acupoint stimulation)
Number of subjects: 90
Study 24144572 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (AS, sham, control)
Number of subjects: 90
Study 22160143 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel standard 8‐cm nasal dressing without airway
Number of subjects: 119
Study 22160143 — intervention group
Group type: EXPERIMENTAL
Intervention: Doyle Combo splint (DCS)
Number of subjects: 119
Study 22160143 — intervention group
Group type: EXPERIMENTAL
Intervention: Merocel in a glove finger
Number of subjects: 119
Study 22160143 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaseline gauze
Number of subjects: 119
Study 18723124 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal resuscitation
Number of subjects: 0
Study 17322490 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg calcium supplementation
Number of subjects: 33
Study 17322490 — intervention group
Group type: COMPARATOR
Intervention: No calcium supplementation
Number of subjects: 33
Study 15216448 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg acarbose
Number of subjects: 30
Study 15216448 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 30
Study 11576153 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 11
Study 11576153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 9668930 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption (abstinent, moderate, heavy drinking)
Number of subjects: 0
Study 9668930 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco use
Number of subjects: 0
Study 9668930 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis methods (complete and average linkage with cosine similarity)
Number of subjects: 0
Study 8091142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bid
Number of subjects: 570
Study 8091142 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg bid (subgroup of N = 123)
Number of subjects: 570
Study 8091142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 8091142 — intervention group
Group type: COMPARATOR
Intervention: Placebo (subgroup of N = 123)
Number of subjects: 570
Study 3384970 — intervention group
Group type: EXPERIMENTAL
Intervention: Anxiety Induction
Number of subjects: 40
Study 3384970 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression Induction
Number of subjects: 40
Study 3384970 — intervention group
Group type: EXPERIMENTAL
Intervention: Hostility Induction
Number of subjects: 40
Study 3384970 — intervention group
Group type: COMPARATOR
Intervention: Neutral Induction
Number of subjects: 40
Study 3384970 — intervention group
Group type: EXPERIMENTAL
Intervention: Mood Reversal
Number of subjects: 40
Study 31800490 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary open strategy for port implantation
Number of subjects: 1159
Study 31800490 — intervention group
Group type: COMPARATOR
Intervention: Closed strategy for port implantation
Number of subjects: 1159
Study 30465817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe (EZE)
Number of subjects: 28
Study 30465817 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe glucuronide metabolite (EZEG)
Number of subjects: 28
Study 28444660 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling
Number of subjects: 8
Study 28444660 — intervention group
Group type: COMPARATOR
Intervention: Exergaming
Number of subjects: 8
Study 25410965 — intervention group
Group type: EXPERIMENTAL
Intervention: PMTO (Parent Management Training-the Oregon model)
Number of subjects: 102
Study 25410965 — intervention group
Group type: COMPARATOR
Intervention: SAU (services usually offered in the communities)
Number of subjects: 102
Study 23216762 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial gravity (AG) exercise countermeasure (CM) group, exposed to AG for 30 min, twice daily, with ergometric exercise at 40 W intensity.
Number of subjects: 12
Study 23216762 — intervention group
Group type: COMPARATOR
Intervention: Control group (no AG exercise training).
Number of subjects: 12
Study 21983379 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy smokers
Number of subjects: 32
Study 21983379 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 32
Study 21983379 — intervention group
Group type: COMPARATOR
Intervention: Light smokers
Number of subjects: 32
Study 19238653 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-800088 (doses > or = 0.75 microg/kg)
Number of subjects: 40
Study 19238653 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-800088 (doses 2.5 and 3.0 microg/kg)
Number of subjects: 40
Study 19238653 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-800088 (two highest doses)
Number of subjects: 40
Study 19238653 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 19238653 — intervention group
Group type: EXPERIMENTAL
Intervention: RWJ-800088
Number of subjects: 40
Study 17044763 — intervention group
Group type: EXPERIMENTAL
Intervention: TTM-based expert system intervention (three individualized expert system reports and a stage-matched manual over 6 months)
Number of subjects: 1227
Study 17044763 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 1227